Literature DB >> 23609771

Region-specific regulation of 5-HT1B receptors in the rat brain by chronic venlafaxine treatment.

R Vidal1, A Diaz, A Pazos, E Castro.   

Abstract

RATIONALE: Venlafaxine is a non-selective serotonin and noradrenaline reuptake inhibitor antidepressant drug for which clinical studies have suggested a high level efficacy and a possible early action onset compared to the classical antidepressants. Its therapeutic effects might be due, at least in part, to adaptive changes in serotonergic neurotransmission, through the activation of the different 5-HT receptor subtypes. 5-HT(1B) receptors are located in the axon terminals of both serotonergic and non-serotonergic neurons, where they act as inhibitory autoreceptors or heteroreceptors, respectively. However, the information about the involvement of this subtype in the mechanism of action of antidepressants is limited and quite controversial.
OBJECTIVES: The aim of this study was to evaluate the effect of venlafaxine (10 mg kg⁻¹ day⁻¹, p.o.) after 21 days of treatment on the density of 5-HT(1B) receptors and their functionality in rat brain.
METHODS: Effects of chronic venlafaxine were evaluated at different levels of 5-HT(1B) receptor by using receptor autoradiography, [³⁵S]GTPγS binding, and the regulation of body temperature induced by selective 5-HT(1B) agonist.
RESULTS: Our results show that venlafaxine induced an increase in sensitivity of 5-HT(1B) receptors in hypothalamus both at G-protein level and the control of core temperature without affecting the receptor density.
CONCLUSIONS: These results demonstrate that adaptive changes on 5-HT(1B) receptors induced by chronic administration of venlafaxine exhibit regional differences suggesting that the hypothalamus might be an important site of drug action.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23609771     DOI: 10.1007/s00213-013-3104-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  53 in total

1.  Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine.

Authors:  W J Inder; T C Prickett; R T Mulder; R A Donald; P R Joyce
Journal:  Psychopharmacology (Berl)       Date:  2001-06       Impact factor: 4.530

Review 2.  5-HT receptor regulation of neurotransmitter release.

Authors:  Klaus B Fink; Manfred Göthert
Journal:  Pharmacol Rev       Date:  2007-12       Impact factor: 25.468

3.  5-Hydroxytryptamine 5-HT1B and 5-HT1D receptors mediating inhibition of adenylate cyclase activity. Pharmacological comparison with special reference to the effects of yohimbine, rauwolscine and some beta-adrenoceptor antagonists.

Authors:  P Schoeffter; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-09       Impact factor: 3.000

4.  Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder.

Authors:  James W Murrough; Shannan Henry; Jian Hu; Jean-Dominique Gallezot; Beata Planeta-Wilson; John F Neumaier; Alexander Neumeister
Journal:  Psychopharmacology (Berl)       Date:  2010-05-18       Impact factor: 4.530

5.  Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat.

Authors:  I Hervás; C M Queiroz; A Adell; F Artigas
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

6.  Chronic fluoxetine reduces serotonin transporter mRNA and 5-HT1B mRNA in a sequential manner in the rat dorsal raphe nucleus.

Authors:  J F Neumaier; D C Root; M W Hamblin
Journal:  Neuropsychopharmacology       Date:  1996-11       Impact factor: 7.853

7.  Effects of chronically administered venlafaxine on 5-HT receptor activity in rat hippocampus and hypothalamus.

Authors:  Eitan Gur; Eliyahu Dremencov; Louis D Van De Kar; Bernard Lerer; Michael E Newman
Journal:  Eur J Pharmacol       Date:  2002-02-01       Impact factor: 4.432

8.  Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Relevance to treatment of obsessive-compulsive disorder.

Authors:  M el Mansari; C Bouchard; P Blier
Journal:  Neuropsychopharmacology       Date:  1995-10       Impact factor: 7.853

Review 9.  The 5-HT1B receptor: behavioral implications.

Authors:  M S Clark; J F Neumaier
Journal:  Psychopharmacol Bull       Date:  2001

10.  3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one: a potent and selective serotonin (5-HT1B) agonist and rotationally restricted phenolic analogue of 5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl)indole.

Authors:  J E Macor; C A Burkhart; J H Heym; J L Ives; L A Lebel; M E Newman; J A Nielsen; K Ryan; D W Schulz; L K Torgersen
Journal:  J Med Chem       Date:  1990-08       Impact factor: 7.446

View more
  1 in total

1.  Changes in intensity of serotonin syndrome caused by adverse interaction between monoamine oxidase inhibitors and serotonin reuptake blockers.

Authors:  Rui Tao; Mary Rudacille; Gongliang Zhang; Zhiyuan Ma
Journal:  Neuropsychopharmacology       Date:  2014-02-28       Impact factor: 7.853

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.